Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | ABL1 | P00519 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | HCK | P08631 | 2/20 | 0.31 |
| ▸ | SRC | P12931 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.31 |
| ▸ | MTOR | P42345 | 2/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.31 |
| ▸ | PRKDC | P78527 | 2/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.31 |
| ▸ | TARS1 | P26639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26781286 | 1.00 | TLR7 (0.32) | TLR7PIK3CDABL1EGFRHCK | |
| SCHEMBL26786104 | 1.00 | TLR7 (0.32) | TLR7PIK3CDABL1EGFRHCK | |
| SCHEMBL29315155 | 0.92 | TLR7 (0.37) | TLR7PIK3CDABL1EGFRHCK | |
| SCHEMBL29314387 | 0.91 | TLR7 (0.34) | TLR7NLRP3 | |
| SCHEMBL29315921 | 0.91 | TLR7 (0.34) | TLR7NLRP3 | |
| SCHEMBL29315014 | 0.90 | NLRP3 (0.32) | NLRP3 | |
| SCHEMBL26781359 | 0.90 | TLR7 (0.34) | TLR7NLRP3TARS1 | |
| SCHEMBL26786882 | 0.90 | TLR7 (0.34) | TLR7NLRP3TARS1 | |
| SCHEMBL26786853 | 0.90 | TLR7 (0.34) | TLR7NLRP3TARS1 | |
| SCHEMBL26789833 | 0.90 | TLR7 (0.37) | TLR7NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3784670-B1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2023-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | TLR7 236/4885PIK3CD 3368/4885ABL1 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.